Boule Diagnostics Second Quarter 2024 Earnings: Misses Expectations

Boule Diagnostics (STO:BOUL) Second Quarter 2024 Results

Key Financial Results

• Revenue: kr137.0m (down 2.5% from 2Q 2023).
• Net loss: kr1.60m (down by 139% from kr4.10m profit in 2Q 2023).
• kr0.04 loss per share (down from kr0.11 profit in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Boule Diagnostics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) was also behind analyst expectations.

Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's shares are down 16% from a week ago.

Risk Analysis

Be aware that Boule Diagnostics is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com